

# Biliary Tract Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/BB79BB0E8A8CEN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: BB79BB0E8A8CEN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Biliary Tract Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Biliary Tract Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Biliary Tract Cancer Understanding

#### Biliary Tract Cancer: Overview

Biliary tract cancer (BTC) is an uncommon and highly fatal malignancy. It is composed of three main different entities; Gall bladder carcinoma (GBC), intrahepatic cholangiocarcinoma (iCC) and extrahepatic cholangiocarcinoma (eCC) sharing different genetic, risk factors and clinical presentation. Multidetector-row computed tomography (MDCT) and magnetic resonance cholangio-pancreatography (MRCP) are the more important diagnostic techniques. Surgery is the only potentially curative therapy but disease recurrence is frequent. Treatment with chemotherapy, radiotherapy or both has not demonstrated survival benefit in the adjuvant setting. Cisplatin plus gemcitabine constitutes the gold standard in metastatic disease. New ongoing studies mainly in the adjuvant and neoadjuvant setting along with molecular research will hopefully help to

improve survival and quality of life of this disease.

'Biliary Tract Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Biliary Tract Cancer pipeline landscape is provided which includes the disease overview and Biliary Tract Cancer treatment guidelines. The assessment part of the report embraces, in depth Biliary Tract Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Biliary Tract Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Tract Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Biliary Tract Cancer.

### Biliary Tract Cancer Emerging Drugs Chapters

This segment of the Biliary Tract Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Biliary Tract Cancer Emerging Drugs

Pembrolizumab: Merck & Co.

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Biliary Tract Cancers.

## Disitamab vedotin: RemeGen

Disitamab Vedotin (RC48) is a novel anti-HER2 antibody-drug conjugate (ADC) which is currently across various solid tumor types. It was the first domestically-developed ADC in China approved by the CDE for clinical development in China. ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells. Currently, it is in Phase II stage of clinical trial evaluation to treat Biliary Tract Cancers.

Further product details are provided in the report.....

## Biliary Tract Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Biliary Tract Cancer drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Biliary Tract Cancer

There are approx. 50+ key companies which are developing the therapies for Biliary Tract Cancer. The companies which have their Biliary Tract Cancer drug candidates in the most advanced stage, i.e. phase III include, Merck & Co.

### Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Biliary Tract Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Biliary Tract Cancer therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Biliary Tract Cancer drugs.

## Biliary Tract Cancer Report Insights

- Biliary Tract Cancer Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

## Biliary Tract Cancer Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

## Key Questions

## Current Treatment Scenario and Emerging Therapies:

How many companies are developing Biliary Tract Cancer drugs?

How many Biliary Tract Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Biliary Tract Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Biliary Tract Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Biliary Tract Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Merck

RemeGen

EMD Serono

SMT bio Co., Ltd.

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Jiangsu HengRui Medicine Co., Ltd.

InnoPharmax Inc.

Lee's Pharmaceutical Limited

Hoffmann-La Roche

Eisai

TerSera Therapeutics LLC

Shanghai Miracogen Inc.

Zymeworks Inc.

Mirati Therapeutics

BeiGene

Bristol-Myers Squibb

Eli Lilly and Company

Ipsen

Threshold Pharmaceuticals

Leap Therapeutics

Hutchison Medipharma Limited

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Daiichi Sankyo

3D Medicines

RaND Biosciences

Incyte Corporation

Sotio a.s.

Carisma Therapeutics Inc

Senhwa Biosciences, Inc.

Seagen

Bolt Biotherapeutics, Inc.

Black Diamond Therapeutics, Inc.

Redx Pharma Plc

Silverback Therapeutics

Taiho Oncology, Inc.

Zai Lab (Shanghai) Co., Ltd.

## Key Products

Pembrolizumab

Disitamab vedotin

Bintrafusp alfa

SMT-NK

HA121-28

SHR1258

D07001

ZKAB001

Atezolizumab

Lenvatinib



telotristat ethyl

MRG003

ZW25

Sitravatinib

Tislelizumab

Nivolumab

Ramucirumab

Nanoliposomal Irinotecan

TH-302

DKN-01

Surufatinib

TQB2450

Trastuzumab deruxtecan

Envafolimab

SC-43

INCB001158

SO-C101

CT-0508

CX-4945

Tucatinib

BDC-1001

BDTX-189

RXC004

SBT6050

TAS0728

Niraparib

## Contents

- Introduction
- Executive Summary
- Biliary Tract Cancer: Overview
  - Causes
  - Mechanism of Action
  - Signs and Symptoms
  - Diagnosis
  - Disease Management
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
  - Comparative Analysis
- Pembrolizumab: Merck & Co.
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- Disitamab vedotin: RemeGen
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
  
- Early Stage Products (Phase I)
  - Comparative Analysis
- RO7119929: Hoffmann-La Roche
  - Product Description
  - Research and Development

Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical and Discovery Stage Products  
Comparative Analysis  
Drug name: Company name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....

Inactive Products  
Comparative Analysis  
Biliary Tract Cancer Key Companies  
Biliary Tract Cancer Key Products  
Biliary Tract Cancer- Unmet Needs  
Biliary Tract Cancer- Market Drivers and Barriers  
Biliary Tract Cancer- Future Perspectives and Conclusion  
Biliary Tract Cancer Analyst Views  
Biliary Tract Cancer Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Biliary Tract Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Biliary Tract Cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Biliary Tract Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/BB79BB0E8A8CEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BB79BB0E8A8CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970